It is found that pre-diagnostic plasma proteomics identified proteins and pathways with modest effect sizes and clear differences between future risk of colon and rectal cancer and motivate site-specific biomarker discovery that distinguishes colon from rectal cancer.
Xin-Yuan Zhang, Jonathan M. Downie, D. Drew et al.· Journal of the National Canc...· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
The combination of immune-modulating, non-ablative doses of radiation therapy with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases.
Leontios Pappas, J. Koenig, B. Yeap et al.· Clinical Cancer Research· 0 citations
High-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared to standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC) in a phase 2 randomized clinical trial.
K. Ng, F. Ou, T. Zemla et al.· Journal of the American Medi...· 0 citations
ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
M. Raeisi, T. André, Q. Shi et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.